Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

1
Multiple Myeloma Therapeutics in Asia-Pacific
Markets to 2021 - Growth Driven by Rising
Prevalence, Continued Success of Velcade,
Revlimid and Emerging Supplementary Treatments
Single User License - 4995 Site User
License - 9990 Corporate User License -
14985 Publication Date - Oct 2015 Pages -
117 To know more details, email to
debora_at_reportstack.com
2
Summary

• Multiple Myeloma (MM) is a hematological
  malignancy characterized by the proliferation of
  plasma cells in the bone marrow. The disease is
  incurable although over the past decade there
  have been significant improvements in therapy,
  driven by a greater understanding of
  pathophysiology. MM represents about 0.81 of
  all cancer cases worldwide and approximately 10
  of all hematological cancers, with incidence
  rates ranging from 0.4 to 5 per 100,000 persons
  in different parts of the world.
• Without any treatment, the median survival of a
  myeloma patient is about six months, but this can
  be extended with the use of various forms of
  treatment. There are now five classes of drugs
  used in the treatment of myeloma
  immunomodulatory drugs, chemotherapy, proteasome
  drugs, Histone Deacetylase (HDAC) inhibitors and
  steroids. Many of the notable drugs in these
  classes

3
Scope
The different segments of patients with MM are
based on their eligibility for an SCT- What
combination therapies are used for various
segments?- What are the dominant mechanisms of
action across marketed products?- Which products
are approved currently in each country and which
ones are likely to be launched within the
forecast period?- Which product is used more in
each country?- Will there be any label
expansions of existing market leaders in any of
the countries?Epidemiology of MM is
significantly different in Asia-Pacific countries
from that in the major markets.- What are the
various epidemiology trends in each country?-
What factors contribute to the overall
epidemiology?
4
Key Benefits
- Understand the clinical context of MM by
considering symptoms, etiology, pathophysiology,
epidemiology, diagnosis, and treatment options.-
Identify the therapeutic strategies, products,
and companies that dominate the current marketed
products landscape and recognize gaps and areas
of unmet need.- Appreciate key pipeline trends
in molecule type, administration route, mechanism
of action, and novelty.- Consider market
opportunities and potential risks by examining
trends in clinical trial size, duration, and
failure rate by stage of development, molecule
type, and mechanism of action.- Recognize the
late-stage pipeline molecules that have
demonstrated strong therapeutic potential by
examining clinical trial data and multi-scenario
product forecast projections.
5
If you are interested...
Contact Debora White Email
debora_at_reportstack.com Ph1-888-789-6604 http/
/www.reportstack.com